On December 30, 2020, a solicitud de patente for a pharmaceutical composition for treating TRPV1 activation-mediated diseases was completó in the United States, bringing the total number of completó applications to three — Korea, the U.S., and PCT. Depending on registration status, la empresa planea extend the patent to China, Europe, Japan, and other regions.
This patent covers the potential of TRPV1 in various pain conditions and allows for expansion into protein therapeutics, terapia génica, and other modalities. It se espera que hold value as a use patent for various pain conditions upon registration.